Antitumor activity of HER-2 inhibitors
SK Rabindran - Cancer letters, 2005 - Elsevier
SK Rabindran
Cancer letters, 2005•ElsevierActivation of intracellular mitogenic signal transduction pathways driven by the ErbB family
of receptor tyrosine kinases has been implicated in a variety of cancers. Amongst these, the
tumorigenic roles of the Epidermal Growth Factor receptor (EGFR) and HER-2 have been
most extensively studied. Therapeutic antibodies and small molecule kinase inhibitors
targeting EGFR have recently received regulatory agency approval for the treatment of colon
and lung cancer, respectively. In this review, I briefly describe these agents and their …
of receptor tyrosine kinases has been implicated in a variety of cancers. Amongst these, the
tumorigenic roles of the Epidermal Growth Factor receptor (EGFR) and HER-2 have been
most extensively studied. Therapeutic antibodies and small molecule kinase inhibitors
targeting EGFR have recently received regulatory agency approval for the treatment of colon
and lung cancer, respectively. In this review, I briefly describe these agents and their …
Activation of intracellular mitogenic signal transduction pathways driven by the ErbB family of receptor tyrosine kinases has been implicated in a variety of cancers. Amongst these, the tumorigenic roles of the Epidermal Growth Factor receptor (EGFR) and HER-2 have been most extensively studied. Therapeutic antibodies and small molecule kinase inhibitors targeting EGFR have recently received regulatory agency approval for the treatment of colon and lung cancer, respectively. In this review, I briefly describe these agents and their potential use in inhibiting the growth of tumors that overexpress HER-2. I also discuss other therapeutics currently available or being developed specifically to target HER-2 dependent tumors.
Elsevier